drugset / Trial / NCT05786521

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

NCT05786521

RandomizedParallel-groupOpen-labelBasic science

Summary

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Timeline

Start
2023-04-01
Primary completion
2024-05-20
Completion
2024-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 1 mg